BTAI - BioXcel Therapeutics, Inc.
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 19.32 |
| Open | 19.80 |
| Bid | 19.04 x 800 |
| Ask | 19.30 x 800 |
| Day's Range | 17.70 - 19.25 |
| 52 Week Range | 8.80 - 34.12 |
| Volume | |
| Avg. Volume | 576,395 |
| Market Cap | 550.242M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.97 |
| Earnings Date | Aug 07, 2023 - Aug 11, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 53.00 |
Fair Value
Related Research
Investor's Business DailyBioXcel Stock Crashes 25% As Bid To Double Its Market Appears Less Certain
Shares of BTAI stock plummeted after BioXcel's Igalmi missed the mark in patients with agitation due to schizophrenia or bipolar disorders.
BenzingaBioXcel Therapeutics Stock Tumbles: Company Releases Mixed Results From Lower Dose Igalmi Study In Bipolar/Schizophrenia Associated Agitation
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced results for BXCL501, an orally dissolving film of dexmedetomidine, from Part 1 of Phase 3 SERENITY III trial designed to evaluate BXCL501 in acutely agitated adult patients with bipolar disorders or schizophrenia for at-home use. Part 1 assessed the efficacy and safety of a 60mcg dose, half of the already-approved 120mcg dose (Igalmi). Also Read: BioXcel Therapeutics Reports Encouraging Phase 1b Results For Innovative Depression Treatment. The re
Motley FoolWhy Shares of BioXcel Therapeutics Are Dropping Thursday
Shares of BioXcel Therapeutics (NASDAQ: BTAI) were down more than 19% early Thursday afternoon after the biotech company released the first part of a phase 3 trial for the therapy BXCL501 (dexmedetomidine) to treat acute agitation in bipolar disorders or schizophrenia. The drug, marketed under the name Igalmi (dexmedetomidine), was approved by the Food and Drug Administration (FDA) last April in a sublingual film to treat bipolar and schizophrenia patients in medical settings, but the additional indication was for at-home use. Measured at two hours after the dose, the change in Positive and Negative Syndrome Scale, Excited Component, though it differed from that with placebo, did not reach statistical significance, the company said.
GlobeNewswireBioXcel Therapeutics Announces Promising Topline Results from Part 1 of Pivotal SERENITY III Trial of BXCL501 for At-Home Use in Acute Treatment of Agitation in Bipolar Disorders or Schizophrenia
Clinically meaningful efficacy results observed with half (60mcg) of the approved dose of IGALMI™ Greater than 50% PEC response rate attained; proportionally consistent with dose response when compared to rates seen in SERENITY I and II BXCL501 was well tolerated and demonstrated favorable safety results supporting potential for at-home use SERENITY III Part 2 planned as an adaptive trial design with 60mcg and 80mcg to potentially address agitation spectrum for patients at home Company to hold c
- GlobeNewswire
BioXcel Therapeutics Announces Positive Top-Line Data from Repeat Dosing of BXCL501 in Phase 1b Multiple Ascending Dose Trial in Healthy Volunteers for Major Depressive Disorder (MDD) Program
BXCL501 was well tolerated across a broad dose range from 30mcg to 140mcg administered chronically Planning Phase 2 human proof-of-concept study to evaluate BXCL501 as a potential adjunctive treatment in MDD Data further supportive of ongoing clinical programs evaluating BXCL501 for potential at-home use for agitation associated with schizophrenia or bipolar disorders (SERENITY III) and agitation associated with Alzheimer’s disease (TRANQUILITY II and III) NEW HAVEN, Conn., May 16, 2023 (GLOBE N
Motley FoolWhy These 3 Nasdaq Stocks Were Glowing Green This Week
Despite another less-than-stellar Consumer Price Index report and more volatility among regional bank stocks, growth equities, on balance, were on the upswing this week. The tech-heavy Nasdaq Composite, for instance, edged higher by nearly 3% during the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence. Among the best performers within the growth stock landscape this week were biopharmaceuticals.
Zacks Small Cap ResearchBTAI: Three Data Readouts Expected in the Near Term…
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Data Readouts for Three Clinical Trials in Near Future BioXcel Therapeutics, Inc. (NASDAQ:BTAI) lead development compound, BXCL501, is currently being evaluated in multiple clinical trials. We anticipate important data readouts from three trials in the near term: • Topline data is anticipated in May 2023 from Part
- Thomson Reuters StreetEvents
Q1 2023 BioXcel Therapeutics Inc Earnings Call
Q1 2023 BioXcel Therapeutics Inc Earnings Call
Motley FoolWhy BioXcel Therapeutics Stock Marched Higher Today
The biotech's Q1 earnings report set the stage for a flurry of important clinical updates in the coming months.
Investor's Business DailyHighly Rated Axsome Surges On Earnings Beat. And Here's Why BioXcel Reversed.
Axsome and BioXcel issued divergent earnings reports Monday, but BTAI stock reversed an earlier dive and rose alongside AXSM stock.
- GlobeNewswire
BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights
IGALMI™ (dexmedetomidine) commercial momentum accelerating with doubling of formulary wins, unlocking more than $55 million in targeted market opportunity, and an additional $255 million scheduled to vote Top-line data from pivotal SERENITY III Phase 3 trial (Part 1) for BXCL501 in bipolar or schizophrenia-associated agitation for at-home use expected in May 2023 Top-line data from repeat dosing of BXCL501 in Phase 1b trial for Major Depressive Disorder program in healthy volunteers expected in
Investor's Business DailyThe Next Evolution In Drugs? It's Artificial Intelligence, Says This CEO
BioXcel is banking on artificial intelligence to gain a second speedy FDA approval — and BTAI stock is soaring on the possibility.
- GlobeNewswire
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Tuesday, May 9, 2023 at 10:15 a.m. PT. He will be joined by Robert Risinger, M.D., Chie
- GlobeNewswire
BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023
NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter 2023 financial results on Monday, May 8, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:00 AM ET that day to d
Zacks Small Cap ResearchBTAI: Important Data Readouts in 2Q23…
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Multiple Data Readouts in 2Q23 BioXcel Therapeutics, Inc. (NASDAQ:BTAI) lead development compound, BXCL501, is currently being evaluated in multiple clinical trials. We anticipate important data readouts from three trials in the second quarter of 2023: • Topline data is anticipated from the TRANQUILITY II trial of
- GlobeNewswire
OnkosXcel Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
NEW HAVEN, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- OnkosXcel Therapeutics, LLC (“OnkosXcel”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common stock following its conversion into a corporation. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering
Simply Wall St.BioXcel Therapeutics, Inc. (NASDAQ:BTAI): When Will It Breakeven?
BioXcel Therapeutics, Inc. ( NASDAQ:BTAI ) is possibly approaching a major achievement in its business, so we would...
- Thomson Reuters StreetEvents
Q4 2022 BioXcel Therapeutics Inc Earnings Call
Q4 2022 BioXcel Therapeutics Inc Earnings Call
- GlobeNewswire
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
IGALMI™ (dexmedetomidine) commercial execution fully underway in 2023 with key focus on market access and demand generation through expanded field team Multiple pivotal data readouts for BXCL501 expected in Q2 2023 in disease areas with 139 million agitation episodes,1-3*including Alzheimer’s-related agitation Positive data for BXCL701 in small cell neuroendocrine metastatic castration-resistant prostate cancer (SCNC) further validates Company’s AI drug discovery and development expertise; Compa
- GlobeNewswire
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023 before the open of the U.S. financial markets. BioXcel Therapeutics’ management team will also host a conference call and webcast at 8:30 A
- GlobeNewswire
BioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell Today
NEW HAVEN, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, additional members of the management team, and other BioXcel team members will ring the closing bell of the Nasdaq Stock Market today, Tuesday, February 21, 2023. “At BioXcel Therapeutics,
BenzingaBioXcel Therapeutics Unveils Complete Data From BXCL701/Keytruda Combo Study In Prostate Cancer Subtype
BioXcel Therapeutics Inc (NASDAQ: BTAI) announced full data from its Phase 2a trial of BXCL701 in combination with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients. The trial included patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer. In the evaluable patient cohort (n = 28), 7 (25%) patients achieved a composite response, the t
- GlobeNewswire
BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers Symposium
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrated composite response rate of 25% in patients with metastatic SCNC-variant castration-resistant prostate cancer Company plans to initiate randomized trial evaluating BXCL701 plus pembrolizumab versus BXCL701 monotherapy NEW HAVEN, Conn., Feb. 13, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-
BenzingaAnalyst Reiterates This Alzheimer's Candidate As Top Idea For 2023
Mizuho raised the price target on BioXcel Therapeutics Inc (NASDAQ: BTAI) from $24 to $38, with a Buy rating. Since the analyst's previous model update last December, BTAI shares have meaningfully outperformed vs. its peers (+61% vs +8% for the XBI), based on increased bullishness ahead of the first Phase 3 data for lead asset Igalmi/BXCL501 in Alzheimer's disease (AD) agitation (expected in 1H23). The analyst revisited the BTAI model based on BXCL501 in schizophrenia, bipolar disorder, AD, and
- GlobeNewswire
BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company’s Investigational, Oral Innate Immune Activator for Rare Form of Prostate Cancer
NEW HAVEN, Conn., Feb. 08, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Key Opinion Leader (KOL) Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET. Vimal Mehta, Ph.D., Chief Executive Officer, and Vincent